Neuregulin-1 (Neuregulin 1)

A peptide factor originally identified by its ability to stimulate the phosphorylation the erbB-2 receptor (RECEPTOR, ERBB-2). It is a ligand for the erbB-3 receptor (RECEPTOR, ERBB-3) and the erbB-4 receptor. Variant forms of NEUREGULIN-1 occur through alternative splicing of its mRNA.
Also Known As:
Neuregulin 1; GGF Protein; Differentiation Factor, neu; Glial Growth Factor; Heregulin; NDF Protein; NRG1 Protein; neu Differentiation Factor
Networked: 695 relevant articles (8 outcomes, 90 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Lupu, Ruth: 13 articles (11/2015 - 08/2002)
2. Karl, Tim: 12 articles (05/2015 - 02/2008)
3. Ford, Byron D: 11 articles (10/2015 - 09/2004)
4. Carroll, Steven L: 10 articles (04/2014 - 01/2003)
5. Karl, T: 9 articles (09/2014 - 06/2007)
6. Law, Amanda J: 9 articles (09/2014 - 04/2006)
7. Nawa, Hiroyuki: 9 articles (01/2014 - 09/2006)
8. Waddington, John L: 9 articles (05/2012 - 01/2006)
9. Menendez, Javier A: 8 articles (11/2015 - 01/2005)
10. Huang, Xu-Feng: 8 articles (05/2015 - 08/2009)

Related Diseases

1. Schizophrenia (Dementia Praecox)
2. Breast Neoplasms (Breast Cancer)
3. Neoplasms (Cancer)
03/01/2007 - "ErbB2 and ErbB3, two members of the ErbB family, form a high-affinity heregulin coreceptor that elicits potent mitogenic and transforming signals, and clinical studies indicate that these receptors play an important role in tumor incidence and progression. "
01/01/2000 - "The purpose of the present study was to elucidate the mechanisms by which anti-HER2 antibody and heregulin inhibit tumor growth. "
09/01/2015 - "This Position Paper of the Working Group on Drug Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology aims to: (1) define the distinctive etiopatogenetic features of cardiac toxicity induced by cancer therapy in humans, which include new aspects of mitochondrial function and oxidative stress, neuregulin-1 modulation through the ErbB receptor family, angiogenesis inhibition, and cardiac stem cell depletion and/or dysfunction; (2) review the new, more promising therapeutic strategies for cardioprotection, aimed to increase the survival of patients with severe antineoplastic-induced cardiotoxicity; (3) recommend the distinctive pathological features of cardiotoxicity induced by cancer therapy in humans that should be present in animal models used to identify or to test new cardioprotective therapies. "
03/01/2015 - "Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models."
02/28/2015 - "Collectively these data suggest mechanisms by which the HER3-HER2 dimer promotes development of metastatic tumors in the heregulin-rich brain microenvironment. "
4. Mood Disorders (Mood Disorder)
5. Heart Failure

Related Drugs and Biologics

1. Epidermal Growth Factor Receptor (EGF Receptor)
2. Nerve Growth Factor (NGF)
3. corrole
4. histidine-rich proteins
5. Epidermal Growth Factor (EGF)
6. Phosphotransferases (Kinase)
7. Messenger RNA (mRNA)
8. Protein-Tyrosine Kinases (Tyrosine Kinase)
9. Ligands
10. Carrier Proteins (Binding Protein)

Related Therapies and Procedures

1. Nerve Crush
2. Heterologous Transplantation (Xenotransplantation)
3. Drug Therapy (Chemotherapy)
4. Transplants (Transplant)
5. Transplantation (Transplant Recipients)